RGC

Regencell Bioscience Holdings Limited is a company operating in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. With a market capitalization of $13.37B and an employee count of 10, it is a relatively large player in its field. The company's financial health is marked by significant losses, with net income totaling -$3,584,213 and EBITDA at -$3,692,293 for the trailing twelve months. Free cash flow has also been negative, standing at -$1,507,277. However, Regencell Bioscience Holdings Limited maintains a substantial amount of cash on hand, totaling $4.90M, while debt is relatively modest at $544,415. Regencell Bioscience Holdings Limited's valuation metrics are notable for their extreme values. The price to book ratio stands at 2704.00, indicating significant discrepancies between the company's market value and its underlying equity. Additionally, the EV/EBITDA ratio is -2749.63, suggesting concerns about profitability and potential issues with debt or other liabilities.